Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.06.2012 | Epidemiology

Family history and risk of breast cancer: nurses’ health study

verfasst von: Graham A. Colditz, Kimberly A. Kaphingst, Susan E. Hankinson, Bernard Rosner

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Family history of cancer remains underused in general clinical practice. We assess age at diagnosis and the role of family history in risk of breast cancer. Prospective follow-up of nurses’ health study participants from 1980 to 2006. Updated assessment of family history in mother and sister including age at diagnosis. We used youngest age at diagnosis for family member when classifying risk. We confirmed 4327 incident invasive breast cancers confirmed. Breast cancer incidence models fitted to women with and without family history to assess variation in the risk for established risk factors. Compared to women with no family history those whose mother was diagnosed before age 50 had an adjusted relative risk of 1.69 (95% CI 1.39–2.05) and those with mother diagnosed at 50 or older had a relative risk of 1.37 (1.22–1.53). Sister history was associated with increased relative risk; 1.66 (1.38–1.99) for those with sister history before age 50 and 1.52 (1.29–1.77) for those with sister diagnosed at age 50 or older. Women with either mother or sister diagnosed before age 50 had a relative risk of 1.70 (1.48–1.95) significantly higher than those with diagnosis at age 50 or older (RR = 1.30; (1.27–1.54), P = 0.016). The magnitude of risk associated with established reproductive and lifestyle risk factors did not differ significantly between women with and those without family history with the exception of risk after bilateral oophorectomy in which setting women with family history had greater reduction in risk of subsequent breast cancer. Women with a family member diagnosed with breast cancer before age 50 had increased risk of breast cancer compared to women with family members diagnosed at older ages. Consistent findings for risk factors regardless of family history adds to robust evidence for risk identification and risk stratification in clinical settings where prevention strategies will apply equally to women with and without family history.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW (2010) Cancer screening in the United States, 2010: a review of current American cancer society guidelines and issues in cancer screening. CA Cancer J Clin 60(2):99–119. doi:10.3322/caac.20063 PubMedCrossRef Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW (2010) Cancer screening in the United States, 2010: a review of current American cancer society guidelines and issues in cancer screening. CA Cancer J Clin 60(2):99–119. doi:10.​3322/​caac.​20063 PubMedCrossRef
3.
Zurück zum Zitat Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712PubMedCrossRef Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712PubMedCrossRef
5.
Zurück zum Zitat Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA (1993) Family history, age, and risk of breast cancer. Prospective data from the nurses’ health study. JAMA 270(3):338–343PubMedCrossRef Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA (1993) Family history, age, and risk of breast cancer. Prospective data from the nurses’ health study. JAMA 270(3):338–343PubMedCrossRef
6.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399. doi:10.1016/S0140-6736(01)06524-2 Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399. doi:10.​1016/​S0140-6736(01)06524-2
7.
Zurück zum Zitat Colditz G, Rosner B, Speizer F (1996) Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 88:365–371PubMedCrossRef Colditz G, Rosner B, Speizer F (1996) Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 88:365–371PubMedCrossRef
8.
Zurück zum Zitat Colditz GA, Hankinson SE (2005) The nurses’ health study: lifestyle and health among women. Nat Rev Cancer 5(5):388–396PubMedCrossRef Colditz GA, Hankinson SE (2005) The nurses’ health study: lifestyle and health among women. Nat Rev Cancer 5(5):388–396PubMedCrossRef
9.
Zurück zum Zitat Colditz G, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the nurses’ health study. Am J Epidemiol 152(10):950–964PubMedCrossRef Colditz G, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the nurses’ health study. Am J Epidemiol 152(10):950–964PubMedCrossRef
10.
Zurück zum Zitat Floderus B, Barlow L, Mack TM (1990) Recall bias in subjective reports of familial cancer. Epidemiology 1(4):318–321PubMedCrossRef Floderus B, Barlow L, Mack TM (1990) Recall bias in subjective reports of familial cancer. Epidemiology 1(4):318–321PubMedCrossRef
12.
Zurück zum Zitat Mai PL, Garceau AO, Graubard BI, Dunn M, McNeel TS, Gonsalves L, Gail MH, Greene MH, Willis GB, Wideroff L (2011) Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst 103(10):788–797. doi:10.1093/jnci/djr114 PubMedCrossRef Mai PL, Garceau AO, Graubard BI, Dunn M, McNeel TS, Gonsalves L, Gail MH, Greene MH, Willis GB, Wideroff L (2011) Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst 103(10):788–797. doi:10.​1093/​jnci/​djr114 PubMedCrossRef
14.
Zurück zum Zitat Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE (1986) Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123:894–900PubMed Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE (1986) Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123:894–900PubMed
15.
Zurück zum Zitat SEER (1995) SEER cancer statistics review: 1973–1992. National Cancer Institute, Bethesda SEER (1995) SEER cancer statistics review: 1973–1992. National Cancer Institute, Bethesda
16.
Zurück zum Zitat Emery JD, Walter FM, Ravine D (2010) Family history: the neglected risk factor in disease prevention. Med J Aust 192(12):677–678PubMed Emery JD, Walter FM, Ravine D (2010) Family history: the neglected risk factor in disease prevention. Med J Aust 192(12):677–678PubMed
17.
Zurück zum Zitat Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87. doi:10.1093/jnci/djn442 PubMedCrossRef Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87. doi:10.​1093/​jnci/​djn442 PubMedCrossRef
18.
Zurück zum Zitat Campa D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, Berg CD, Buring JE, Chanock SJ, Diver WR, Dostal L, Fournier A, Hankinson SE, Henderson BE, Hoover RN, Isaacs C, Johansson M, Kolonel LN, Kraft P, Lee IM, McCarty CA, Overvad K, Panico S, Peeters PH, Riboli E, Sanchez MJ, Schumacher FR, Skeie G, Stram DO, Thun MJ, Trichopoulos D, Zhang S, Ziegler RG, Hunter DJ, Lindstrom S, Canzian F (2011) Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst 103(16):1252–1263. doi:10.1093/jnci/djr265 PubMedCrossRef Campa D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, Berg CD, Buring JE, Chanock SJ, Diver WR, Dostal L, Fournier A, Hankinson SE, Henderson BE, Hoover RN, Isaacs C, Johansson M, Kolonel LN, Kraft P, Lee IM, McCarty CA, Overvad K, Panico S, Peeters PH, Riboli E, Sanchez MJ, Schumacher FR, Skeie G, Stram DO, Thun MJ, Trichopoulos D, Zhang S, Ziegler RG, Hunter DJ, Lindstrom S, Canzian F (2011) Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst 103(16):1252–1263. doi:10.​1093/​jnci/​djr265 PubMedCrossRef
20.
Zurück zum Zitat Zoorob R, Anderson R, Cefalu C, Sidani M (2001) Cancer screening guidelines. Am Fam Physician 63(6):1101–1112PubMed Zoorob R, Anderson R, Cefalu C, Sidani M (2001) Cancer screening guidelines. Am Fam Physician 63(6):1101–1112PubMed
22.
Zurück zum Zitat Preventive Services Task Force (2002) Screening for breast cancer: recommendations and rationale. Ann Intern Med 137:344–346 Preventive Services Task Force (2002) Screening for breast cancer: recommendations and rationale. Ann Intern Med 137:344–346
24.
Zurück zum Zitat Yoon PW, Scheuner MT, Jorgensen C, Khoury MJ (2009) Developing family healthware, a family history screening tool to prevent common chronic diseases. Prev Chronic Dis 6(1):A33PubMed Yoon PW, Scheuner MT, Jorgensen C, Khoury MJ (2009) Developing family healthware, a family history screening tool to prevent common chronic diseases. Prev Chronic Dis 6(1):A33PubMed
25.
Zurück zum Zitat Dunlop K, Barlow-Stewart K (2010) ‘Start the conversation’: the New South Wales (Australia) family health history campaign. Public Health Genomics 13(5):301–309. doi:10.1159/000253121 PubMedCrossRef Dunlop K, Barlow-Stewart K (2010) ‘Start the conversation’: the New South Wales (Australia) family health history campaign. Public Health Genomics 13(5):301–309. doi:10.​1159/​000253121 PubMedCrossRef
28.
Zurück zum Zitat Eliassen AH, Colditz G, Rosner B, Willett W, Hankinson SE (2006) Adult weight change and risk of postmenopausal breast cancer. JAMA 296:193–201PubMedCrossRef Eliassen AH, Colditz G, Rosner B, Willett W, Hankinson SE (2006) Adult weight change and risk of postmenopausal breast cancer. JAMA 296:193–201PubMedCrossRef
29.
Zurück zum Zitat Willett WC, Stampfer MJ (1997) Sobering data on alcohol and breast cancer. Epidemiology 8:225–227PubMed Willett WC, Stampfer MJ (1997) Sobering data on alcohol and breast cancer. Epidemiology 8:225–227PubMed
Metadaten
Titel
Family history and risk of breast cancer: nurses’ health study
verfasst von
Graham A. Colditz
Kimberly A. Kaphingst
Susan E. Hankinson
Bernard Rosner
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-1985-9

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.